BioHarvest Sciences (BHST)

Sunday

1:43 PM

ThesisRecent partnerships and technological advancements are expected to enhance production efficiency and market access, shifting investor sentiment positively.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$35M	$37M	$50M
Rev. Growth	+37.0%	+8.4%	+32.5%
EPS	$-0.60	$-0.53	$-0.34
EPS Growth	+25.0%	+12.1%	+36.5%
P/E	—	—	—

★ Analysts see FY2027 revenue reaching $50M — +32.5% growth in a single year.

The Bull Case for Growth

01Recent advancements in cell-culture technology have increased production efficiency by 25%, potentially reducing costs significantly.
02A new partnership with a major health supplement distributor is expected to increase market access by 40%.
03Regulatory approval for a new cannabinoid product line is anticipated, which could unlock a $100 million market opportunity.
04Growing consumer preference for plant-based health products
05Expansion of the legal cannabis market in North America
06Regulatory changes in cannabis markets, particularly in North America
07Advancements in proprietary technology that enhance production efficiency
08Partnerships or contracts with major distributors in the nutraceutical space

FY2025 Snapshot

Revenue: $35M
Rev. Growth: +37.0%
Gross Margin: 59.3%
Op. Margin: -16.2%
Net Margin: -32.3%
Net Income: $-11M
NI Growth: +13.8%
EPS: $-0.60
1Y Return: -78.1%

My Notes

"Our innovative technology positions us to capitalize on the growing demand for plant-based products."
Moat: BioHarvest's proprietary technology provides a significant barrier to entry, though competitors are rapidly innovating.
growth - Investors looking for exposure to the expanding cannabis and nutraceutical markets may find BioHarvest appealing despite current…
Higher interest rates could increase financing costs for BioHarvest, impacting its ability to invest in growth and potentially affecting its…
Watch on earnings: Cannabinoid market growth rate, Operating cash flow trends, Gross margin improvements.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $37M to $50M as recent advancements in cell-culture technology have increased production efficiency by 25%.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.